Hard to Treat Diseases (HTDS) Awarded Two Antibiotics Certificates For Chile

SHENZHEN, CHINA, March 15 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS; http://www.htdsmedical.com/) is pleased to announce that the Chilean government approved two of the company's penem injectables.

Following 18 months of testing and negotiations, Chilean ISP (Ministry of Health) approved two of HTDS' penem injectables, Meropenem for Injection (MEINEN) and Imipenem for Injection (IMINEN). HTDS received the registration certificate for these two medications from the Chilean ISP and the company prepares to ship its products to this emerging South American market. Meropenem and Imipenem See link http://www.cdc.gov/ncidod/dhqp/ar_lab_imipenem.html are antibiotics with wide range of efficiency, treating infections in lungs, heart, blood, bone, stomach, etc., and offer great market value for the producers and distributors.

HTDS' CEO Terry Yuan said, "We are happy that we finalized the test stage for these two products and received the ISP's certificate. The certificate will strengthen our supply capacity for the market. HTDS - Mellow Hope through our Chilean agent holds a powerful position on the local injectables market. Aligning these two facts, we believe that these two antibiotics will succeed in Chile and bring solid sales numbers to HTDS. Overall, penem injectables have great market potential globally, and we continue to seek new market and distribution opportunities around the world." More on penem injectables can be found by visiting www.oxfordjournals.org

The company reminds our shareholders and followers that the company does not subscribe to the PinkSheets.com Filing Service. Its IR company web site section "CLIENT SUPPORT" TAB www.minamargroup.net or this direct link http://minamarmarketinggroup.helpserve.com/should be reviewed by its followers for further updates on this and other business matters. Non-newsworthy events are not press released however posted on this separate support sites to keep our followers advised of day-to-day events, and the company corporate web site. For any matters relating to retail investor queries or to send us the company directly a message please click on the "INVESTOR SUPPORT" TAB or this direct link www.minamargroup.net/helpdesk.

To be included in company's email database for press releases, industry updates, and non-weekly activity at the company that may or may not be news released, please subscribe or opt in mailer at www.minamargroup.com/updates.

Safe Harbor Statement

Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For medical and scientific dialogue inquiry only, please contact [email protected]; For any corporate matters, please contact www.minamargroup.com/helpdesk

SOURCE Hard to Treat Diseases